Owkin partners with Stanford Medicine on lung cancer and mesothelioma treatment research using AI
Using Stanford Medicine’s multimodal patient data, including molecular data, the research aims to discover new biomarkers to improve the development of new treatments. It also aims to further the understanding of treatment-resistance mechanisms and identify potential treatment targets. Owkin, who is sponsoring the research, is contributing its expertise in AI to the study.
The research is led by principal investigator Olivier Gevaert, PhD, Associate Professor of Medicine at the Stanford School of Medicine.
Dinesh Divakaran, VP of Partnerships, North America at Owkin, said:
The convergence of cutting-edge AI and high-quality patient data is fuelling a revolution in cancer research. We are excited to work with Stanford Medicine to further our mission of using AI to find the right treatment for every patient.
By combining our expertise in AI with Stanford Medicine’s high-quality multimodal patient data, we hope to better understand the treatment of lung cancer and mesothelioma and make a lasting difference to the lives of patients worldwide.
About Owkin
Owkin is the first end-to-end AI biotech company on a mission to understand complex biology and ensure every patient gets the right treatment.
We identify precision therapeutics, de-risk and accelerate clinical trials, and develop diagnostics using AI trained on world-class patient data through privacy-enhancing technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular disease, and immunity and inflammation.
Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research across nine cancer indications.
Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like F-Prime, GV and Bpifrance, among others.
